BLOOD CANCER

The following clinical trials related to blood cancers are available through the WPAHS. Please click on the link for more detailed information on the trial. Below each trial is the contact information at the WPAHS.

Leukemia Trials

 

Acute Lymphocytic Leukemia (ALL)

Study Title

A Phase II Trial Of Sequential Chemotherapy, Imatinib Mesylate (Gleevec, STI571) (NSC # 716051, IND # 61135), And Transplantation For Adults With Newly Diagnosed PH+ Acute Lymphoblastic Leukemia By The CALGB And SWOG

 

Principal Investigator: John Lister, M.D.

Please also contact study coordinator for more information:

Lisa Wilt, RN, BSN (Phone 412-578-4429)

Internal Reference: (WPCI 2002-09/CALGB C10001 Lister)

_______________________________________________

Acute Myelogenous Leukemia (AML)

Study Title

Phase II Study of Maintenance Therapy With Decitabine (NSC #127716, IND #50733) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients With AML < 60 Years

 

Principal Investigator: John Lister, M.D.

Please also contact study coordinator for more information:

Lisa Wilt, RN, BSN  (Phone 412-578-4429)

Internal Reference: ( WPCI 2007-01/CALGB 10503 Lister)

 

Study Title

A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML)

 

Principal Investigator: John Lister, M.D.

Please also contact study coordinator for more information:

Lisa Wilt, RN, BSN (Phone 412-578-4429)

Internal Reference: (WPCI-2008-15/CALGB 10603 Lister)

 

Study Title

Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration

 

Principal Investigator: James Rossetti, M.D.

Please also contact study coordinator for more information:

Kari Ham RN, CCRC (Phone 412-688-7584)

Internal Reference: ( WPCI-2009-03/Celator  Rossetti)

 

Study Title

Phase III Open-Label Randomized Study of Amonafide L-Malate in Combination With Cytarabine Compared to Daunorubicin in Combination With Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- The ACCEDE Study

 

Principal Investigator: James Rossetti, M.D.

Please also contact study coordinator for more information:

Lisa Wilt, RN, BSN (Phone 412-578-4429)

Internal Reference: ( WPCI-2008-24/Antisoma  Rossetti)

_______________________________________________

Myelodysplastic Syndrome (MDS)

Study Title

A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

 

Principal Investigator: James Rossetti, M.D.

Please also contact study coordinator for more information:

Rich Wonder, RN, CCRC (Phone 412-204-8125)

Internal Reference: ( WPCI-2009-02/Amgen  Rossetti)

 

Lymphoma Trials

Study Title

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (Bortezomib) in Combination With Rituximab, Cyclophosphamide, and Prednisone With or Without Doxorubicin Followed by Rituximab Maintenance in Patients With Relapsed Follicular Lymphoma.

 

Principal Investigator: John Pawloski, M.D. and John Lister, M.D.

This trial is offered at both Allegheny General and Western Pennsylvania Hospital

Please also contact study coordinator for more information:

AGH

Susan Hebda, CRA (Phone 412-359-8162)

Internal Reference: (RC-4741 Pawloski)

___________________________________________________

WP

Laura Gibson, RN, CCRC (Phone 412-578-4439)

Internal Reference:  (C05012/WPCI 2008-10  Lister)

 

Study Title

An Open-label, Single-arm Phase II Study of RAD001 in Patients With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® (Bortezomib)

 

Principal Investigator: John Lister, M.D.

Please also contact study coordinator for more information:

Jean Goy RN, BSN, CCRC (Phone 412 578- 4588-)

Internal Reference: (WPCI 2008-08/CRAD001N2201  Lister)

 

Study Title

Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas

 

Principal Investigator: John Lister, M.D.

Please also contact study coordinator for more information:

Jean Goy RN, BSN, CCRC (Phone 412-578-4588)

Internal Reference: ( WPCI 2006-18/CALGB 50303 Lister)

 

Study Title

An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

 

Principal Investigator: John Lister, M.D.

Please also contact study coordinator for more information:

Kari Ham RN, CCRC (Phone 412-688-7584)

Internal Reference: ( WPCI 2009-04/Cephalon and PPD International   Lister)

 



West Penn Allegheny Cancer Institute Home
Cancer Care
Our SpecialistsClinical Trials
Cancer InfoAbout UsContact Us
Visit the West Penn Allegheny Health System

© West Penn Allegheny Health System

Privacy Statement | Legal Disclaimer

This website is for informational purposes only and not intended as medical advice or a substitute for a consultation with a professional healthcare provider.